Journal
NATURE REVIEWS CANCER
Volume 13, Issue 5, Pages 299-314Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3496
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC) of Australia programme and project grants
- Leukemia Foundation Grant in Aid
- Prostate Cancer Foundation of Australia grant in aid
- NHMRC Research Fellowship
- NHMRC Postgraduate Research Scholarship
- GSK Postgraduate Research Scholarship
- Leukemia Foundation Postdoctoral Fellowship
- Cancer Council of Victoria Sir Edward Weary Dunlop Clinical Research Fellowship
- NHMRC Clinical Research Fellowship
Ask authors/readers for more resources
Mutations that directly affect transcription by RNA polymerases rank among the most central mediators of malignant transformation, but the frequency of new anticancer drugs that selectively target defective transcription apparatus entering the clinic has been limited. This is because targeting the large protein-protein and protein-DNA interfaces that control both generic and selective aspects of RNA polymerase transcription has proved extremely difficult. However, recent technological advances have led to a 'quantum leap' in our comprehension of the structure and function of the core RNA polymerase components, how they are dysregulated in a broad range of cancers and how they may be targeted for 'transcription therapy'.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available